子宫肌瘤剔除术后应用米非司酮防止复发的效果评价

The Therapeutic Evaluation of Mifepristone on Preventing Recurrence of Uterine Myomas After Myomectomy

目的 评价子宫肌瘤剔除术后应用米非司酮预防复发的效果。方法 将35～40岁行子宫肌瘤剔除术的患者设为观察组，于术后第1次转经时服用米非司酮12．5mg/天，连续3个月，次年再用1疗程；随机选取既往单纯行子宫肌瘤剔除术的有随访资料的病例为对照组。结果 观察组62例，6例复发，较对照组（8／26）显著低（P〈0．05）。观察组51例恢复正常月经，与对照组（16／26）相比差异有统计学意义（P〈0．05）。结论 子宫肌瘤剔除术后服用米非司酮可有效防止复发，改善月经过多症状。

Objective To assess the effects of Mifepristone on the prevention of recurrence of uterine myomas after myomectomy. Methods The cases prepared for myomectomy of 35 - 40 years within treatment groups were treated with Mifepristone from first menses after surgery, 12.5 mg each day lasted for 3 months, and repeated for one course of treatment next year. The cases with complete follow-up result after hysterectomy were randomized into control groups. Results The relapse in the first group was 9.68 % （6/62）, significantly lower than that in the second group 30.77 % （8/26）. 51 cases resumed normal menses, which was significant compared with the control groups（ P 〈 0.05） .Conclusions Oral Mifepristone is an effective treatment in preventing recurrence and and improving symptoms of menorrhagia after myomectomy.